Gain Therapeutics (GANX) Short-Term Debt issuances (2022 - 2026)

Gain Therapeutics has reported Short-Term Debt issuances for 5 years, with the latest figure at $25297.0 in Q2 2026.

• On a quarterly basis, Short-Term Debt issuances rose 4.37% year-over-year to $25297.0 in Q2 2026; TTM through Jun 2026 was $100843.0, a 9.17% increase from a year earlier, with the FY2025 full-year figure at $96501.0, up 6.19% from the prior year.
• Short-Term Debt issuances was $25297.0 for Q2 2026 at Gain Therapeutics, down from $25525.0 in the prior quarter.
• The five-year high for Short-Term Debt issuances was $37974.0 in Q1 2022, with the low at -$1363.0 in Q2 2022.
• Average Short-Term Debt issuances over 5 years is $22557.9, with a median of $22705.0 recorded in 2023.
• The largest YoY upside for Short-Term Debt issuances was 1732.13% in 2023 against a maximum downside of 43.09% in 2023.
• Over 5 years, Short-Term Debt issuances stood at $21582.0 in 2022, then advanced by 4.62% to $22579.0 in 2023, then rose by 0.89% to $22780.0 in 2024, then climbed by 9.86% to $25025.0 in 2025, then rose by 1.09% to $25297.0 in 2026.
• The last three Short-Term Debt issuances figures came in at $25297.0 (Q2 2026), $25525.0 (Q1 2026), and $25025.0 (Q4 2025), per Business Quant data.